Antibody-drug conjugate development succeeds or fails on integration, not any single component. This guide examines what development teams need to align before first-in-human testing and throughout clinical development: target biology and antigen expression, antibody-linker-payload design, drug-to-antibody ratio trade-offs, biomarker/assay strategy, dose and schedule rationale (per FDA guidance and Project Optimus), safety monitoring for ADC-specific toxicities, and CMC comparability planning. Recent Phase III readouts (CLARITY-Gastric01, TROPION-Lung01, ASCENT-03) illustrate why endpoint design, population selection, and full safety data matter as much as a positive topline result. The post Antibody-Drug Conjugate Development: From Molecular Design to Clinical Proof appeared first on Allucent .